Skip to Main Content

Merck will continue to search out more acquisitions after its $11 billion purchase of biotech firm Acceleron Pharma, the company’s CEO told STAT in an interview Thursday.

But the CEO, Rob Davis, said he also believes that investors have not yet come to realize the value of the experimental drugs Merck is developing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment